Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
Antibodies generated against West Nile virus (WNV) during infection are essential for controlling dissemination. Recent studies have demonstrated that epitopes in all three domains of the flavivirus envelope protein (E) are targets for neutralizing antibodies, with determinants in domain III (DIII) eliciting antibodies with strong inhibitory properties. In order to increase the magnitude and quality of the antibody response against the WNV E protein, DNA vaccines with derivatives of the WNV E gene (full length E, truncated E, or DIII region, some in the context of the pre-membrane [prM] gene) were conjugated to the molecular adjuvant P28. The P28 region of the complement protein C3d is the minimum CR2-binding domain necessary for the adjuvant activity of C3d. Delivery of DNA-based vaccines by gene gun and intramuscular routes stimulated production of IgG antibodies against the WNV DIII region of the E protein. With the exception of the vaccine expressing prM/E given intramuscularly, only mice that received DNA vaccines by gene gun produced protective neutralizing antibody titers (FRNT80 titer >1/40). Correspondingly, mice vaccinated by the gene gun route were protected to a greater level from lethal WNV challenge. In general, mice vaccinated with P28-adjuvated vaccines produced higher IgG titers than mice vaccinated with non-adjuvanted vaccines.
Dunn
Matthew D
MD
Center for Vaccine Research, University of Pittsburgh, 9047 Biomedical Science Tower 3, Pittsburgh, PA 15261, USA.
Rossi
Shannan L
SL
Carter
Donald M
DM
Vogt
Matthew R
MR
Mehlhop
Erin
E
Diamond
Michael S
MS
Ross
Ted M
TM
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D002460:Cell Line; D002522:Chlorocebus aethiops; D015933:Complement C3d / Q000008:administration & dosage / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D017434:Protein Structure, Tertiary; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014901:West Nile Fever / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D014902:West Nile virus / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; D015933:Complement C3d
Adv Virus Res. 2008;72:77-126
19081489
AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):829-35
11429124
Nat Immunol. 2000 Aug;1(2):127-31
11248804
Med Microbiol Immunol. 2007 Dec;196(4):227-31
17377815
Emerg Infect Dis. 2002 Dec;8(12):1392-7
12498653
Virology. 2004 Oct 25;328(2):292-300
15464849
Vaccine. 1997 Jun;15(8):785-7
9234513
J Virol. 2007 Dec;81(23):12816-26
17881453
J Immunol. 2007 Mar 1;178(5):2699-705
17312111
Vaccine. 2003 Feb 14;21(9-10):902-14
12547601
Nat Med. 2005 May;11(5):522-30
15852016
Science. 2003 Oct 10;302(5643):248
14551429
J Invest Dermatol. 2001 Sep;117(3):702-9
11564180
MMWR Morb Mortal Wkly Rep. 2008 Jul 4;57(26):720-3
18600197
Cell Host Microbe. 2007 Apr 19;1(2):135-45
18005691
Expert Opin Biol Ther. 2004 Aug;4(8):1295-305
15268663
PLoS Pathog. 2009 May;5(5):e1000453
19478866
Vaccine. 2009 Jul 9;27(32):4370-80
19497647
Curr HIV Res. 2005 Apr;3(2):191-8
15853723
Eur J Immunol. 2007 Jul;37(7):1845-54
17559174
Immunol Res. 2006;36(1-3):197-210
17337780
Nat Struct Biol. 2003 Nov;10(11):907-12
14528291
J Exp Med. 2003 Dec 15;198(12):1853-62
14662909
J Virol. 2009 Jul;83(13):6494-507
19386704
J Invest Dermatol. 1998 Aug;111(2):183-8
9699714
J Virol. 2006 Dec;80(24):12149-59
17035317
Vaccine. 2005 May 16;23(26):3469-76
15837370
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9568-72
2175906
Proc Assoc Am Physicians. 1999 May-Jun;111(3):211-9
10354361
J Virol. 2006 Nov;80(22):11000-8
16943291
J Virol. 2001 Apr;75(8):4002-7
11264392
J Virol. 2008 Jan;82(2):927-37
18003724
J Virol. 2001 May;75(9):4040-7
11287553
J Virol. 2006 Dec;80(23):11467-74
16987985
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6986-91
12759475
EMBO J. 2003 Jun 2;22(11):2604-13
12773377
Nat Med. 1996 Oct;2(10):1122-8
8837611
J Immunol. 2008 Dec 15;181(12):8568-75
19050276
J Virol. 2007 Jun;81(11):6141-5
17376919
Vaccine. 2009 Oct 30;27(46):6444-53
19580892
Virology. 2003 Sep 15;314(1):190-5
14517072
Nature. 2004 Jan 22;427(6972):313-9
14737159
J Virol. 2006 Oct;80(19):9349-60
16973541
Viral Immunol. 2000;13(4):401-10
11192286
Vaccine. 2009 Nov 16;27(49):6905-9
19761840
J Virol. 2004 May;78(9):4710-9
15078953
J Infect Dis. 2004 Dec 15;190(12):2104-8
15551208
J Virol. 2007 Nov;81(21):11828-39
17715236
DNA Cell Biol. 1993 Nov;12(9):791-7
8216850
Vaccine. 2001 Oct 12;20(1-2):242-8
11567770
J Virol. 2003 Feb;77(3):2046-55
12525639
Adv Exp Med Biol. 2006;586:249-64
16893077
Dev Biol (Basel). 2003;114:221-7
14677692
J Virol. 2003 Feb;77(4):2578-86
12551996
Vaccine. 2008 Jan 10;26(2):153-7
18069096
J Virol. 2002 Dec;76(24):13097-100
12438639
Microbes Infect. 2009 Nov;11(13):1019-28
19647801
Eur J Immunol. 2007 Jul;37(7):1855-63
17559175
Cell Host Microbe. 2007 Dec 13;2(6):417-26
18078693
Nature. 1995 May 25;375(6529):291-8
7753193
J Virol. 2007 Sep;81(17):9551-5
17582005
J Invest Dermatol. 2000 Mar;114(3):560-8
10692118
Curr Opin Mol Ther. 2007 Oct;9(5):498-504
17932814
Cell Host Microbe. 2009 Oct 22;6(4):381-91
19837377
Vaccine. 2004 Apr 16;22(13-14):1773-81
15068861
J Infect Dis. 2007 Dec 15;196(12):1732-40
18190252